ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Study Summary

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Conditions

Bladder Carcinoma Ureter Carcinoma Renal Pelvis Carcinoma Non-small Cell Lung Cancer Invasive Breast Carcinoma Cutaneous Melanoma Esophageal Carcinoma Gastroesophageal Junction Carcinoma Gastric Adenocarcinoma Pancreatic Adenocarcinoma Squamous Cell Carcinoma of the Head and Neck Epithelial Ovarian Carcinoma Fallopian Tube Carcinoma Endometrial Carcinoma Renal Cell Carcinoma Rectal Adenocarcinoma

Interventions / Drugs

Guardant Reveal

View on ClinicalTrials.gov ↗

Sponsor

Guardant Health

Oncology Diagnostics

D41/100

Study Details

Enrollment2020 participants

Primary Completion—

Lead SponsorGuardant Health, Inc.

Data Retrieved2026-04-11 04:14:36.379965+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.